CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-19 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −1,991 | $14.36 | $29K | 865,922 |
| 2023-07-19 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −13,150 | $15.36 | $202K | 852,772 |
| 2023-07-19 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −9,859 | $16.00 | $158K | 842,913 |
| 2023-07-19 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 670,313 | ||
| 2023-07-18 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 855,413 |
| 2023-07-18 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −24,500 | $13.62 | $334K | 830,913 |
| 2023-07-18 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −500 | $14.05 | $7K | 830,413 |
| 2023-07-18 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 707,813 | ||
| 2023-07-18 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +30,000 | $2.22 | $67K | 173,954 |
| 2023-07-18 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −30,000 | $13.74 | $412K | 143,954 |
| 2023-07-18 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −30,000 | 509,469 | ||
| 2023-07-17 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +30,000 | $2.22 | $67K | 173,954 |
| 2023-07-17 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −30,000 | $11.72 | $352K | 143,954 |
| 2023-07-17 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −30,000 | 539,469 | ||
| 2023-07-13 | Burrell Terry-Ann Director | Sale | −8,275 | $12.59 | $104K | 54,847 |
| 2023-07-12 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 947,628 |
| 2023-07-12 | Gibson Christopher Chief Executive Officer | Sale | −3,423 | $10.87 | $37K | 944,205 |
| 2023-07-12 | Gibson Christopher Chief Executive Officer | Sale | −7,898 | $11.80 | $93K | 936,307 |
| 2023-07-12 | Gibson Christopher Chief Executive Officer | Sale | −3,270 | $12.39 | $41K | 933,037 |
| 2023-07-12 | Gibson Christopher Chief Executive Officer | Sale | −17,227 | $14.34 | $247K | 915,810 |
Page 35 of 41 · 805 trades